Edition:
United States

Aap Implantate AG (AAQG.DE)

AAQG.DE on Xetra

1.17EUR
24 Mar 2017
Change (% chg)

-- (--)
Prev Close
€1.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
27,518
52-wk High
€1.70
52-wk Low
€1.16

Latest Key Developments (Source: Significant Developments)

aap Implantate 2016 sales and EBITDA below guidance
Tuesday, 21 Mar 2017 09:58am EDT 

aap Implantate AG : Sales by 514,000 euros ($555,993.80) and EBITDA by 450,000 euros slightly below guidance for financial year 2016 due to failure of distributor to fulfil contractual duties . Announces that in course of drawing up annual financial statements for 2016 management board decided as a precautionary measure to revoke an initial sale with a distribution partner invoiced in financial year . Reason is a delayed payment of contractual due purchase price .In continued operation in financial year 2016 sales are at 10.5 million euros and EBITDA at -7.9 million euros and thereby slightly below current guidance.  Full Article

aap Implantate Q4 sales stable at 2.4 million euros
Wednesday, 1 Mar 2017 02:28am EST 

aap Implantate AG : Said on Tuesday achieved prelim sales of 2.4 million euros ($2.53 million) in the continued operation in the fourth quarter of 2016 (Q4/2015: 2.4 million euros) . Sales of 11.2 million euros in the continued operation in financial year 2016 as a whole (FY/2015: 12.3 million euros) .Forecast for FY/2017: sales between 10.0 million euros and 13.0 million euros and EBITDA between -6.5 million euros and 4.5 million euros; dynamic development expected from the second half of the year.  Full Article

Aap Implantate will not achieve previous FY 2016 sales and EBITDA forecast for continued operation
Thursday, 15 Dec 2016 04:39am EST 

Aap Implantate AG : aap updates forecast for financial year 2016 due to delays in sales development in various markets . Announces that it will not achieve previous sales and EBITDA forecast for financial year 2016 for continued operation . Adjusts its forecast for financial year 2016 for continued operation and now anticipates sales between 11.0 million euros and 12.1 million euros ($12.71 million)as well as an EBITDA of -7.5 million to -7.0 million euros . For 2016 EBITDA of group (continued and discontinued operation including deconsolidation profit from sale of aap biomaterials gmbh) company anticipates a value of between 16.5 million and 17.0 million euros . Management board aims at a ce approval and closing of a license deal in financial year 2017 which will have visible influence on financial figures .Reasons for this adjustment are delays in sales development in various markets leading to a sales shift in financial year 2017.  Full Article

Aap Implantate post Q2 EBITDA loss from continued oprations of 1.4 mln euros
Friday, 12 Aug 2016 11:27am EDT 

Aap Implantate AG : In the continued operation sales and EBITDA in Q2/2016 at 3.4 million euros ($3.80 million) (guidance: 2.5 million euros to 3.5 million euros) and -1.4 million euros (guidance: -2.5 million euros to -1.5 million euros) respectively . In Q3 of 2016, aap aims to achieve further progress in its strategy implementation .For Q3 of 2016, aap is expecting for continued operation sales to range between 2.5 million euros and 4.0 million euros and an EBITDA of -2.0 million euros to -1.2 million euros.  Full Article

Aap Implantate now sees FY EBITDA of 18.1 - 19.7 million euros
Wednesday, 10 Aug 2016 03:42am EDT 

Aap Implantate AG : Deconsolidation profit from the sale of Aap Biomaterials GmbH leads to an increase of 2016 EBITDA forecast for the group . Sees FY 2016 EBITDA of group of between 18.1 million and 19.7 million euros (previously between 14.1 million and 15.7 million euros) .Now sees FY EBITDA of continued operation of between -5.9 million and -4.3 million euros.  Full Article

aap Implantate Q1 sales down at 5.1 million euros
Monday, 16 May 2016 02:29am EDT 

AAP Implantate AG : Said on Saturday Q1 sales 5.1 million euros ($5.77 million) (Q1/2015: 7.1 million euros) . For Q1 posted an EBITDA of -1.9 million euros (Q1/2015: 0.2 million euros) .Confirms its forecast for 2016: anticipates for the EDITDA of the Group (continued and discontinued operation) incl. deconsolidation gain a value of between 14.1 million and 15.7 million euros.  Full Article

Aap Implantate gets about EUR 36.6 mln from sale of biomaterials business
Wednesday, 11 May 2016 11:09am EDT 

Aap Implantate AG : Receives proceeds of about 36.6 million euros ($41.83 million) from sale of biomaterials business . Completion of transaction will result in a positive one-time overall effect on earnings level of 19 million - 20 million euros .Company will use part of proceeds to finance further growth and to distribute part of them to its shareholders.  Full Article

aap Implantate comments on FY 2016 outlook
Friday, 29 Apr 2016 08:00pm EDT 

aap Implantate AG:Sees FY 2016 sales of between 13.0 million and 15.0 million euros in the continued operation with 20 pct growth in trauma products.Sees FY 2016 EBITDA of between -5.5 million and -3.9 million euros for the continued operation.Sees FY 2016 EBITDA of the Group (continued and discontinued operation) incl. deconsolidation gain of between 14.1 million and 15.7 million euros.  Full Article

aap Implantate sells biomaterials business for 36 mln euros
Monday, 21 Mar 2016 09:21pm EDT 

aap Implantate AG:Sells biomaterials business for 36 million euros and becomes a pure player in trauma with innovative technologies.The closing of the transaction will result in a positive one-time deconsolidation effect on the earnings level.Plans to use part of the proceeds to finance further growth and to distribute part of them to its shareholders.  Full Article

aap Implantate gives Q1 2016 forecast; gives full FY 2016 outlook with EBITDA outlook below analysts' estimates
Thursday, 18 Feb 2016 10:38am EST 

aap Implantate AG:Sales forecast for FY/2016 between 30 million euros and 34 million euros.Sees ‍EBITDA of 0.0 million euros to 1.0 million euros for financial year 2016​.‍Outlook for financial year 2016: aims for more than 20 pct trauma sales growth​.‍Cost reduction planned in all divisions except sales​.‍For Q1 of 2016 management board anticipates sales of 4.5 million euros to 6.0 million euros and an EBITDA of -2.0 million euros to -1.0 million euros.FY 2016 revenue estimate 34.95 million euros - Thomson Reuters I/B/E/S.FY 2016 EBITDA estimate 3.52 million euros - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-aap Implantate 2016 sales and EBITDA below guidance

* Sales by 514,000 euros ($555,993.80) and EBITDA by 450,000 euros slightly below guidance for financial year 2016 due to failure of distributor to fulfil contractual duties